Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
GREENSBORO, N.C., Sept. 21, 2016 -- Mucodel Pharma LLC (“Mucodel”) today announced the successful completion of a pilot clinical study involving buccal naloxone (Exonal™), a Mucodel product under development for the reversal of opioid overdose.
Exonal™ employs Mucodel’s Co-Gel platform for oromucosal delivery of pharmaceutically active agents and is particularly suitable for rescue therapeutics requiring rapid absorption.
The pilot pharmacokinetic study compared Exonal™ buccal naloxone with an approved intramuscular injectable naloxone.
The study met its objectives and demonstrated that Exonal™ rapidly delivered the targeted naloxone dose, with comparable Cmax and Tmax to the approved intramuscular injectable reference product.
Founder and CEO, Dr. Madhu Hariharan, stated: “We are pleased with the pilot clinical results for Exonal™ buccal naloxone. The remarkably rapid transit of naloxone through the buccal mucosal barrier for this critical rescue therapy speaks very well for our Co-Gel platform technology.”
Joseph Fuisz, head of business development, stated: “Exonal™ buccal naloxone offers a series of substantial value added features as compared with existing treatment options including improved reliability and ease of administration. Dosing placement can be readily taught and seen.”
Naloxone is a Food and Drug Administration (FDA) approved agent that treats the effects of opioid overdose caused by the use or misuse of prescription and illicit opioids. US deaths from opioid overdose currently exceed 8 per 100,000, are increasing further and are on track to eclipse automobile fatalities (10.25 per 100,000). The majority of deaths occur at home.
Currently, there is no approved naloxone rescue product with an oromucusol route of administration. FDA approved formulations of rescue naloxone include injectable products and a nasal spray.
About Mucodel Pharma:
The mission of Mucodel is to develop improved rescue therapies that are oromucosally administered. Mucodel’s proprietary Co-Gel technology allows for oromucosal administration of existing drugs that would not otherwise be amenable to oromucosal delivery. Mucodel’s Co-Gel platform enables more convenient products and offers tangible therapeutic benefits to patients.
Mucodel is a private company based in Greensboro, North Carolina. www.mucodel.com
Media Contact: Madhu Hariharan [email protected] Business Development Contact: Joseph Fuisz [email protected]
